- Home
- AIRS vs RIGL Comparison
AIRS vs RIGL Comparison
Compare AIRS & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- RIGL
- Stock Information
- Founded
- AIRS 2012
- RIGL 1996
- Country
- AIRS United States
- RIGL United States
- Employees
- AIRS N/A
- RIGL N/A
- Industry
- AIRS Medical/Nursing Services
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- RIGL Health Care
- Exchange
- AIRS Nasdaq
- RIGL Nasdaq
- Market Cap
- AIRS 400.5M
- RIGL 486.4M
- IPO Year
- AIRS 2021
- RIGL 2000
- Fundamental
- Price
- AIRS $5.35
- RIGL $17.09
- Analyst Decision
- AIRS Hold
- RIGL Buy
- Analyst Count
- AIRS 2
- RIGL 5
- Target Price
- AIRS $5.00
- RIGL $34.80
- AVG Volume (30 Days)
- AIRS 237.8K
- RIGL 189.6K
- Earning Date
- AIRS 11-08-2024
- RIGL 11-07-2024
- Dividend Yield
- AIRS N/A
- RIGL N/A
- EPS Growth
- AIRS N/A
- RIGL N/A
- EPS
- AIRS N/A
- RIGL 0.22
- Revenue
- AIRS $188,780,000.00
- RIGL $157,374,000.00
- Revenue This Year
- AIRS N/A
- RIGL $48.98
- Revenue Next Year
- AIRS $10.31
- RIGL $14.43
- P/E Ratio
- AIRS N/A
- RIGL $76.64
- Revenue Growth
- AIRS N/A
- RIGL 21.65
- 52 Week Low
- AIRS $2.92
- RIGL $7.48
- 52 Week High
- AIRS $9.20
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- AIRS 38.88
- RIGL 30.82
- Support Level
- AIRS $5.58
- RIGL $16.68
- Resistance Level
- AIRS $6.60
- RIGL $19.80
- Average True Range (ATR)
- AIRS 0.58
- RIGL 1.53
- MACD
- AIRS -0.15
- RIGL -1.05
- Stochastic Oscillator
- AIRS 0.43
- RIGL 3.66
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. At Elite Body Sculpture, company provide custom body contouring using proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.